Source comparison
BPC-157 for Torn Rotator Cuff: Injury Severity Comparison
Partial tear (< 50% thickness) 8–12 weeks to pain-free ROM, 16–20 weeks to full strength 6–8 weeks to pain-free ROM, 10–14 weeks to full strength 60–70% return to pre-injury tensile strength, recurrent pain with overhead activity 80–90% return to pre-injury te
This comparison does not assign a generated winner or score.
- Partial tear (< 50% thickness)
- 8–12 weeks to pain-free ROM, 16–20 weeks to full strength
- 6–8 weeks to pain-free ROM, 10–14 weeks to full strength
- 60–70% return to pre-injury tensile strength, recurrent pain with overhead activity
- 80–90% return to pre-injury tensile strength, minimal residual weakness
- BPC-157 offers the greatest relative benefit for partial tears. It shifts the healing trajectory from scar-dominant to collagen-dominant before tissue remodeling is complete.
- Full-thickness tear (< 1 cm)
- Surgical repair typically recommended; conservative management rarely restores function
- 10–14 weeks to functional ROM with structured rehab, strength gains plateau at 70–75% baseline
- Conservative management fails in 85% of cases. Chronic pain, instability, progressive tear enlargement
- Peptide alone does not replace surgical repair for full-thickness tears, but it accelerates post-surgical recovery and may prevent tear progression in non-surgical candidates
- For small full-thickness tears, BPC-157 is adjunctive to either surgical repair or intensive PT. Not a standalone solution.
- Degenerative tendinopathy (chronic, no acute tear)
- 12–24 weeks of eccentric loading + manual therapy, high recurrence rate (40–50%)
- 6–10 weeks with peptide + eccentric protocol, lower recurrence (estimated 20–30% based on tendon remodeling markers)
- Persistent low-grade pain, limited overhead endurance, flare-ups with activity spikes
- Improved pain-free ROM, greater tolerance for loading, reduced inflammatory flare frequency
- Chronic tendinopathy responds well to BPC-157 because the peptide addresses the underlying vascular insufficiency that perpetuates the degenerative cycle.